Skip to content

Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye

Paralysis of the Orbicularis Muscle of the Eye by Using Botulinum Toxin Type A in the Treatment for Dry Eye

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02403219
Enrollment
20
Registered
2015-03-31
Start date
2013-05-31
Completion date
2015-01-31
Last updated
2015-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Keywords

Dry eye, Botulinum toxin A, Orbicularis muscle of the eye

Brief summary

This is a prospective, comparative, contralateral eye study. Patients older than 18 years who have had treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein were included. Patients with dry eye attributable to abnormalities of the eyelids, nasolacrimal obstruction and active corneal infection, as well as patients with severe dry eye were excluded from the study. One eye randomly received a subcutaneous injection of botulinum toxin in the medial part of the lower eyelid, and the other eye received a similar procedure with placebo. The subjective evaluation was achieved with a questionnaire assessing symptoms of dry eye and conjunctivitis, quality of vision and ocular comfort level each eye separately. The objective evaluation included the measurement of the tear film break up time, Schirmer's test and with a modification of the Oxford grading scheme for corneal and conjunctival staining.

Interventions

Injection of botulinum toxin type A

Injection of saline solution

Sponsors

Instituto de Oftalmología Fundación Conde de Valenciana
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein.

Exclusion criteria

* Dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.) * Nasolacrimal obstruction. * Active corneal infection. * Patients with severe grade 4 dry eye.

Design outcomes

Primary

MeasureTime frameDescription
Symptoms of dry eye (questionnaire)6 monthsA questionnaire assessing symptoms of dry eye each eye separately, including dryness, watery eyes, itching, burning, foreign body, fluctuating vision and light sensitivity. Depending on the frequency, each symptom will be graded from 0 to 5.
Symptoms of conjunctivitis (questionnaire)6 monthsA questionnaire assessing symptoms of conjunctivitis eye separately, including redness and discharge. Depending on the frequency, each symptom will be graded from 0 to 5.
Quality of vision (graded perception of patient)6 monthsThe quality of vision will be graded from 0 to 5 according to the perception of the patient.
Ocular comfort level (graded perception of patient)6 monthsThe ocular comfort level will be graded from 0 to 5 according to the perception of the patient.
Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)6 monthsThe
Visual acuity (Snellen vision acuity)6 monthsSnellen vision acuity
Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)6 monthsAfter fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking will be recorded in seconds.
Schirmer's test6 monthsAfter instillation of topical anesthetic, paper strips are inserted into the conjunctival sac for 5 minutes to measure the production of tears in millimeters.
Oxford grading scheme for corneal and conjunctival staining6 monthsAfter fluorescein staining, the corneal and conjunctival staining will be graded according to severity from 0 to 5.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026